Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053293 · ClinicalTrials.gov registry record · Early Phase 1
SGLT2i, Hepatic Glucose Production, and SNS
A Early Phase 1 study of Type 2 Diabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT07053293 is a Early Phase 1 study of Type 2 Diabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 22 participants, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07053293, a Early Phase 1 study of Type 2 Diabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. Principal Investigator (PI) will conduct five distinct experiments to test this hypothesis in patients with T2D. To examine the role of the SNS on the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D by comparing the effect of empagliflozin versus empagliflozin plus propranolol.
Conditions Studied
Interventions
- DRUG Empagliflozin 25 MG
Study Locations (1)
Texas
- Texas Diabetes Institute/UH - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2027-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053293
The ClinicalTrials.gov registry entry for NCT07053293 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,103-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Empagliflozin 25 MG is the first listed.
NCT07053293 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07053293 about?
NCT07053293 is a clinical study titled "SGLT2i, Hepatic Glucose Production, and SNS". In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by ...
What is the current status of trial NCT07053293?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2025-01-07. Estimated completion is 2027-06-30.
What conditions does trial NCT07053293 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07053293?
The interventions under investigation include: Empagliflozin 25 MG (DRUG).
Who is sponsoring clinical trial NCT07053293?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07053293 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
-
Precision Dosing of Metformin in Youth With T2D
RECRUITING · Early Phase 1
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
RECRUITING · Early Phase 1
-
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction
RECRUITING · Early Phase 1
-
Antioxidant Treatment of Type 2 Diabetes
COMPLETED · Early Phase 1
-
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.